Immunic CEO on Q1 Highlights, New Appointments and Upcoming Milestones

Why It Matters

The upcoming phase‑3 results and secured financing could propel Immunic into a leading commercial player in multiple sclerosis, offering a novel neuroprotective therapy and unlocking further pipeline value.

Key Takeaways

• New CMO Michael Panzara joins, boosting neurology expertise.
• Board adds John Congleton, Thor Nagel; Simona Skirjanek interim chair.
• $400M oversubscribed financing signals strong investor confidence in opportunity.
• Phase 3 readouts for Ensure 1/2 due end‑year; NDA targeted 2027.
• Drug VETA activates NUR1, promising neuroprotection for relapsing and progressive MS.

Summary

Immunic’s CEO Daniel Witt used the Proactive interview to outline a busy first quarter, highlighting a slate of senior appointments, a $400 million oversubscribed financing round, and the company’s roadmap toward commercializing its lead candidate, VETA calcium. The new chief medical officer, Dr. Michael Panzara, brings multiple‑sclerosis expertise, while board additions John Congleton and Thor Nagel, and interim chair Simona Skirjanek, signal a governance shift aimed at guiding the firm through the final phase‑3 readouts and an NDA filing slated for 2027.

Witt emphasized that the company is transitioning from a development‑focused entity to a commercial‑stage organization. The two pivotal phase‑3 trials, Ensure 1 and Ensure 2, each enrolling roughly 1,100 relapsing‑MS patients, are expected to read out by year‑end, providing the data needed for regulatory submission. He also underscored VETA’s novel mechanism as the first NUR1 activator, offering direct neuroprotective effects that could extend to progressive‑MS indications, a potential expansion of the drug’s market.

Notable remarks included, “game‑changing potential of the drug,” and “we have reached an inflection point where investor confidence reflects the data and the opportunity.” Witt stressed the importance of educating patients, physicians, and the public about this new mode of action, while committing to hiring additional medical‑affairs and commercial staff to ensure a seamless launch.

The combined leadership overhaul, robust capital raise, and imminent data readouts position Immunic to move swiftly into commercialization, potentially reshaping the MS treatment landscape and creating a platform for future neuroprotective candidates.

Original Description

Immunic Inc (NASDAQ:IMUX, FRA:10VA) CEO Dr Daniel Vitt tells Proactive's Stephen Gunnion that the company is firmly on track to become a commercial-stage biotech, with Phase 3 readouts from its ENSURE-1 and ENSURE-2 relapsing multiple sclerosis trials expected by the end of 2026 and an NDA filing targeted for 2027.

A $400 million oversubscribed financing — with $200 million already in hand — has given Immunic the firepower to see it through. Vitt says the level of investor support reflects confidence in the clinical data and the scale of the opportunity across both relapsing and progressive MS.

New CMO Dr Michael Panzara brings deep neurology expertise to support the final stretch toward potential approval, while fresh board appointments, including seasoned biopharmaceutical executive Jon Congleton and Thor Nagel of BVF Partners, signal growing institutional commitment.

On vidofludimus calcium itself, Vitt is direct: "The drug is the first activator of Nurr1, and with that has the potential to be a direct neuroprotective molecule" — something he describes as having "game-changing potential" for patients.

For more videos like this, visit the Proactive YouTube channel, give this video a like, subscribe to the channel and enable notifications so you never miss future content.

#Immunic #MultipleSclerosis #MSResearch #Biotech #Biotechnology #Healthcare #VidofludimusCalcium #Neurology #ClinicalTrials #Phase3 #Nurr1 #DrugDevelopment #MedTech #PharmaNews #Investing #HealthcareInnovation #ProgressiveMS #RelapsingMS #BiotechStocks #ProactiveInvestors